South Korea Liraglutide Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Victoza, Saxenda, and Others), By Application (Type 2 Diabetes, Obesity, and Others), and South Korea Liraglutide Market Insights, Industry Trend, Forecasts to 2035

South Korea Liraglutide Market Insights Forecasts to 2035

The South Korea Liraglutide Market Size is Expected to Grow at a CAGR of around 6.7% from 2025 to 2035
The South Korea Liraglutide Market Size is Expected to hold a significant Share by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Liraglutide Market Size is Anticipated to Grow at a CAGR of 6.7% from 2025 to 2035. The market is driven by rising prevalence of type 2 diabetes and obesity, coupled with increasing awareness about GLP-1 receptor agonists for effective glycemic control and weight management. Additionally, supportive healthcare policies and growing adoption of advanced diabetes therapies further propel market growth.

Market Overview

The South Korean liraglutide market consists of the pharmaceutical market for liraglutide as a GLP-1 receptor agonist for glycemic control in type 2 diabetes, and chronic weight management in obesity. The market in South Korea is expanding rapidly, propelled by growing diabetes and obesity prevalence, increasing patient awareness, and increasing physician prescribing of GLP-1 therapies to their patients. In addition, access to liraglutide is evolving through hospitals, retail pharmacies and online pharmacy channels, improving and increasing patient uptake through reimbursement and patient assistance programs. Clinical evidence supporting liraglutide with respect to reducing reduced HbA1c, weight and cardiovascular risks are all contributing to production of liraglutide. Although liraglutide has some challenges regarding high treatment costs and the route of administration via injection, liraglutide holds a good opportunity for future growth based on the new formulation and ease of dosing. In combination with a stable Slovak healthcare system, clear and innovative initiatives to manage the chronicity of metabolic diseases in the life science industry, the South Korea liraglutide market will achieve solid long term growth between now and the end of the forecast period of 2035.

Report Coverage

This research report categorizes the market for the South Korea liraglutide market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea liraglutide market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea liraglutide market.

Driving Factors

The South Korea liraglutide market is driven by the rising prevalence of type 2 diabetes and obesity, resulting in a greater necessity for more effective glycemic control and weight management therapies. The evidence and clinical experience supporting liraglutide as the only drug to demonstrate clinically meaningful reduction in HbA1C, lead to weight loss, and improve cardiovascular outcomes is driving physician uptake. Expanded reimbursement coverage from government health plans, patient assistance programs, and increasing awareness by both healthcare professionals and patients, have improved accessibility for patients. Furthermore, growth in hospital, retail, and online pharmacy channels contribute to more prescriptions, thereby allowing for overall market expansion.

Restraining Factors

Market growth is restrained by the high price of liraglutide, the injectable route of administration, and competition from next-generation GLP-1 receptor agonists and multi-agonist drugs. Limited reimbursement in certain patient groups and potential price erosion from generics/biosimilars are also limitations on adoption.

Market Segmentation

The South Korea liraglutide market share is classified into product type and application.

• The victoza segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea liraglutide market is segmented by product type into victoza, saxenda, and others. Among these, the victoza segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. Victoza is an exceedingly popular medication for the management of type 2 diabetes due to its clinically evidenced efficacy in lowering blood glucose levels, enhancing the A1c value, and having cardiovascular advantages.

• The type 2 diabetes segment dominated the market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea liraglutide market is segmented by application into type 2 diabetes, obesity, and others. Among these, the type 2 diabetes segment dominated the market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is a result of the high incidence of diabetes in South Korea, increasing uptake of GLP-1 receptor agonists such as liraglutide and a lot of clinical data supporting improved glycemic controls and weight management outcomes.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea liraglutide market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies 

• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• AstraZeneca
• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Boehringer Ingelheim GmbH
• Novartis AG
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea liraglutide market based on the below-mentioned segments:

South Korea Liraglutide Market, By Product Type

• Victoza
• Saxenda
• Others

South Korea Liraglutide Market, By Application

• Type 2 Diabetes
• Obesity
• Others